E-LIB Suche - Ergebnisse für: Kyi, Chrisann

1

A phase 2 trial of zanidatamab in HER2-overexpressed advanc..:

Lumish, Melissa ; Chui, M. Herman ; Zhou, Qin...
Gynecologic Oncology. 182 (2024) - p. 75-81 , 2024

Link: https://doi.org/10.1016/..

2

A shared neoantigen vaccine combined with immune checkpoint..:

Rappaport, Amy R. ; Kyi, Chrisann ; Lane, Monica...
Nature Medicine. 30 (2024) 4 - p. 1013-1022 , 2024

Link: https://doi.org/10.1038/..

3

Nivolumab for mismatch-repair-deficient or hypermutated gyn..:

Friedman, Claire F. ; Manning-Geist, Beryl L. ; Zhou, Qin...
Nature Medicine. 30 (2024) 5 - p. 1330-1338 , 2024

Link: https://doi.org/10.1038/..

4

Mitogen-Activated Protein Kinase Driven Rare Gynecologic Ca..:

Grisham, Rachel N. ; Praiss, Aaron ; Kyi, Chrisann.
Advances in Oncology. 3 (2023) 1 - p. 47-53 , 2023

Link: https://doi.org/10.1016/..

5

A phase 2, multicenter, open-label study of anti-LAG-3 iera..:

Lin, Chia-Chi ; Garralda, Elena ; Schöffski, Patrick...
OncoImmunology. 13 (2023) 1 - p. , 2023

Link: https://doi.org/10.1080/..

6

Is there a Role for Immunotherapy in Treatment of Cervical ..:

, In: 50 Big Debates in Gynecologic Oncology,

Kyi, Chrisann ; Zamarin, Dmitriy - p. 285-287 , 2023

Link: https://doi.org/10.1017/..

7

Dual targeting ovarian cancer by Muc16 CAR T cells secretin..:

Mun, Sung Soo ; Meyerberg, Jeremy ; Peraro, Leila...
Cancer Immunology, Immunotherapy. 72 (2023) 11 - p. 3773-3786 , 2023

Link: https://doi.org/10.1007/..

8

Assessing the Genomic Landscape of Cervical Cancers: Clinic..:

Friedman, Claire F. ; Ravichandran, Vignesh ; Miller, Kathryn...
Clinical Cancer Research. 29 (2023) 22 - p. 4660-4668 , 2023

Link: https://doi.org/10.1158/..

9

Durvalumab with or without tremelimumab in patients with pe..:

Rubinstein, Maria M. ; Doria, Eric Rios ; Konner, Jason...
Gynecologic Oncology. 169 (2023) - p. 64-69 , 2023

Link: https://doi.org/10.1016/..

10

Gastric-type adenocarcinoma of the cervix: Clinical outcome..:

Ehmann, Sarah ; Sassine, Dib ; Straubhar, Alli M....
Gynecologic Oncology. 167 (2022) 3 - p. 458-466 , 2022

Link: https://doi.org/10.1016/..

11

Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525..:

Schöffski, Patrick ; Tan, Daniel S W ; Martín, Miguel...
Journal for ImmunoTherapy of Cancer. 10 (2022) 2 - p. e003776 , 2022

Link: https://doi.org/10.1136/..

12

Uterine mesenchymal tumors harboring ALK fusions and respon..:

Kyi, Chrisann ; Friedman, Claire F. ; Mueller, Jennifer J....
Gynecologic Oncology Reports. 37 (2021) - p. 100852 , 2021

Link: https://doi.org/10.1016/..

13

A phase I open-label study of selinexor with paclitaxel and..:

Rubinstein, Maria M. ; Grisham, Rachel N. ; Cadoo, Karen...
Gynecologic Oncology. 160 (2021) 1 - p. 71-76 , 2021

Link: https://doi.org/10.1016/..

14

Phase I dose escalation safety and feasibility study of aut..:

Kyi, Chrisann ; Doubrovina, Ekaterina ; Zhou, Qin...
Journal for ImmunoTherapy of Cancer. 9 (2021) 8 - p. e002752 , 2021

Link: https://doi.org/10.1136/..

15

Neoadjuvant nivolumab for patients with resectable HPV-posi..:

Ferris, Robert L ; Spanos, William C ; Leidner, Rom...
Journal for ImmunoTherapy of Cancer. 9 (2021) 6 - p. e002568 , 2021

Link: https://doi.org/10.1136/..